Document is current
Any future updates will be listed below
-
Authors
Fagiolini, Andrea https://orcid.org/0000-0001-5827-0853
Leopold, Karolina
Pappa, Sofia https://orcid.org/0000-0002-6303-1547
Cottam, William J. https://orcid.org/0000-0003-4045-8609
Hickey, Joe https://orcid.org/0009-0004-2669-3447
Rogerson, Olivia
Yildirim, Murat https://orcid.org/0000-0001-6192-1047
Beckham, Clodagh https://orcid.org/0009-0003-2351-2519
-
Funding
Funding for this research was provided by:
Otsuka Pharmaceutical Europe Ltd
H. Lundbeck A/S
- License Information
-
More Information
Article History
Received: 12 December 2024
Accepted: 27 January 2025
First Online: 3 March 2025
Declarations
:
: Andrea Fagiolini is a consultant and/or speaker and/or has received research grants from Angelini, Boehringer Ingelheim, Idorsia, Italfarmaco, Lundbeck, Janssen, Medicamenta, Mylan, Otsuka, Pfizer, Recordati, Rovi, Sunovion, Teva, Viatris. Karolina Leopold has participated on an advisory board and/or speaker and/or research grants from Boehringer Ingelheim, Lundbeck, Janssen, Otsuka, Recordati, Rovi. Sofia Pappa has acted as a consultant, speaker or has received research grants from Lundbeck, Janssen, Otsuka, Recordati, Rovi, Gedeon Richter, Sunovion. William J. Cottam, Joe Hickey, and Olivia Rogerson are all employees of OPEN Health, London, UK. Murat Yildirim is an employee of H. Lundbeck A/S, Valby, Denmark. Clodagh Beckham is an employee of Otsuka Pharmaceutical Europe Ltd., Berkshire, UK.
: The study was conducted by OPEN Health (London, UK), a contract research organisation, in accordance with the ethical principles specified in the Declaration of Helsinki and the requirements of the European Union General Data Protection Regulation. All participants provided electronic informed consent to participate in the survey. No patients were included in the survey, and there was no direct access to patient or patient medical record information; on this basis, Institutional Review Board (IRB) exemption was granted (SALUS IRB; 14 January 2024).
